pneumococcal hormone therapy 2 doses, 2-6 months apart breast cancer 52 y.o. ≥ 140 mg/dL q1-2y mammogram based on life expectancy / health status ≥ 6.5% 40-59 y.o., ASCVD ≥ 10%, low bleeding risk ≥ 40 y.o.; LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors q15y tamoxifen ≥ 20% depression 3% overweight / obesity diabetes < 60 y.o. 40-75 y.o.; LDL > 190 or ASCVD ≥ 10% + ≥ 1 risk factor Hepatitis C aspirin cardiovascular disease 40-75 y.o., ASCVD ≥ 7.5%, ≥ 1 risk factor 40 y.o. ≥ 5.7% women age 55- 64 y.o. 65 y.o. aromatase inhibitors ≤ q2y ≥ 126 mg/dL 40-75 y.o., LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors anxiety Hepatitis B q1y ≥ 200 mg/dL dyslipidemia HIV multidose initial series, then 1 dose at 2-6 months hypertension herpes zoster 75 y.o. colorectal cancer 40-70 y.o., ASCVD ≥ 10%, low bleeding risk cervical cancer 50 y.o. Gail model Timed up and go test tobacco use q5y q2y Fracture Risk Assessment Tool lung cancer community- dwelling, postmenopausal women 60 y.o. 1 dose; 2 doses (2-6 months apart) if immunocomp insufficient evidence for screening ≥ 100 mg/dL dementia q1y mammogram Tyrer- Cuzick model raloxifene ovarian cancer statin q3y PREVENT equation pneumococcal hormone therapy 2 doses, 2-6 months apart breast cancer 52 y.o. ≥ 140 mg/dL q1-2y mammogram based on life expectancy / health status ≥ 6.5% 40-59 y.o., ASCVD ≥ 10%, low bleeding risk ≥ 40 y.o.; LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors q15y tamoxifen ≥ 20% depression 3% overweight / obesity diabetes < 60 y.o. 40-75 y.o.; LDL > 190 or ASCVD ≥ 10% + ≥ 1 risk factor Hepatitis C aspirin cardiovascular disease 40-75 y.o., ASCVD ≥ 7.5%, ≥ 1 risk factor 40 y.o. ≥ 5.7% women age 55- 64 y.o. 65 y.o. aromatase inhibitors ≤ q2y ≥ 126 mg/dL 40-75 y.o., LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors anxiety Hepatitis B q1y ≥ 200 mg/dL dyslipidemia HIV multidose initial series, then 1 dose at 2-6 months hypertension herpes zoster 75 y.o. colorectal cancer 40-70 y.o., ASCVD ≥ 10%, low bleeding risk cervical cancer 50 y.o. Gail model Timed up and go test tobacco use q5y q2y Fracture Risk Assessment Tool lung cancer community- dwelling, postmenopausal women 60 y.o. 1 dose; 2 doses (2-6 months apart) if immunocomp insufficient evidence for screening ≥ 100 mg/dL dementia q1y mammogram Tyrer- Cuzick model raloxifene ovarian cancer statin q3y PREVENT equation
(Print)
pneumococcal
hormone therapy
2 doses, 2-6 months apart
breast cancer
52 y.o.
≥ 140 mg/dL
q1-2y mammogram based on life expectancy / health status
≥ 6.5%
40-59 y.o., ASCVD ≥ 10%, low bleeding risk
≥ 40 y.o.; LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors
q15y
tamoxifen
≥ 20%
depression
3%
overweight / obesity
diabetes
< 60 y.o.
40-75 y.o.; LDL > 190 or ASCVD ≥ 10% + ≥ 1 risk factor
Hepatitis C
aspirin
cardiovascular disease
40-75 y.o., ASCVD ≥ 7.5%, ≥ 1 risk factor
40 y.o.
≥ 5.7%
women age 55-64 y.o.
65 y.o.
aromatase inhibitors
≤ q2y
≥ 126 mg/dL
40-75 y.o., LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors
anxiety
Hepatitis B
q1y
≥ 200 mg/dL
dyslipidemia
HIV
multidose initial series, then 1 dose at 2-6 months
hypertension
herpes zoster
75 y.o.
colorectal cancer
40-70 y.o., ASCVD ≥ 10%, low bleeding risk
cervical cancer
50 y.o.
Gail model
Timed up and go test
tobacco use
q5y
q2y
Fracture Risk Assessment Tool
lung cancer
community-dwelling, postmenopausal women
60 y.o.
1 dose; 2 doses (2-6 months apart) if immunocomp
insufficient evidence for screening
≥ 100 mg/dL
dementia
q1y mammogram
Tyrer-Cuzick model
raloxifene
ovarian cancer
statin
q3y
PREVENT equation
